"Reasonable and necessary" redefined for Medicare
This article was originally published in Clinica
Executive Summary
The US Centers for Medicare and Medicaid Services (CMS) is having another stab at defining what criteria it uses for determining whether a product is "reasonable and necessary", and thus fit to be covered by Medicare. But this time, CMS intends to address the subject as a guidance document similar to those issued by the FDA. In 1989 and again in 2000, the agency proposed addressing the issue through regulation, but backed off both times because of industry's objections to the use of cost effectiveness as an important criteria.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.